Literature DB >> 3597771

Molecular basis for nondeletion alpha-thalassemia in American blacks. Alpha 2(116GAG----UAG).

S A Liebhaber, M B Coleman, J G Adams, F E Cash, M H Steinberg.   

Abstract

An American black woman was found to have the phenotype of moderately severe alpha-thalassemia normally associated with the loss of two to three alpha-globin genes despite an alpha-globin gene map that demonstrated the loss of only a single alpha-globin gene (-alpha/alpha alpha). Several individuals in her kindred with normal alpha-globin gene mapping studies (alpha alpha/alpha alpha) had mild alpha-thalassemia hematologic values consistent with the loss of one to two alpha-globin genes. These data suggested the presence of a nondeletion alpha-thalassemia defect in this family which segregates with the intact alpha alpha gene cluster. An abnormally migrating and highly unstable alpha-globin gene product was demonstrated by in vitro translation of the reticulocyte mRNA from the proposita and this mutant alpha-globin protein was mapped to the alpha 2-globin gene by hybrid-selected translation. The abnormal alpha 2-globin gene was cloned and sequenced. A single base mutation that results in a premature termination codon was identified at codon 116 (GAG----UAG). The defined alpha-globin genotype of the proposita (-alpha/alpha 116UAG alpha) and the positioning of this nonsense mutation at the alpha 2-globin gene locus are fully consistent with the observed alpha-thalassemia phenotype.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3597771      PMCID: PMC442213          DOI: 10.1172/JCI113041

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene.

Authors:  M Grunstein; D S Hogness
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

2.  Hemoglobin Koya Dora: high frequency of a chain termination mutant.

Authors:  W W De Jong; P Meera Khan; L F Bernini
Journal:  Am J Hum Genet       Date:  1975-01       Impact factor: 11.025

3.  A general method for isolation of high molecular weight DNA from eukaryotes.

Authors:  N Blin; D W Stafford
Journal:  Nucleic Acids Res       Date:  1976-09       Impact factor: 16.971

4.  Identification of a nondeletion defect in alpha-thalassemia.

Authors:  Y W Kan; A M Dozy; R Trecartin; D Todd
Journal:  N Engl J Med       Date:  1977-11-17       Impact factor: 91.245

5.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

6.  Haemoglobin Icaria, a new chain-termination mutant with causes alpha thalassaemia.

Authors:  J B Clegg; D J Weatherall; I Contopolou-Griva; K Caroutsos; P Poungouras; H Tsevrenis
Journal:  Nature       Date:  1974-09-20       Impact factor: 49.962

7.  The separation of human and animal hemoglobins by isoelectric focusing in polyacrylamide gel.

Authors:  J W Drysdale; P Righetti; H F Bunn
Journal:  Biochim Biophys Acta       Date:  1971-01-19

8.  alpha-Thalassemia caused by an unstable alpha-globin mutant.

Authors:  S A Liebhaber; Y W Kan
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

9.  Comparison of methodologies for thalassemia screening by Hb A2 quantitation.

Authors:  R M Schmidt; D L Rucknagel; T F Necheles
Journal:  J Lab Clin Med       Date:  1975-11

10.  Authentic beta-globin mRNA sequences in homozygous betaO-thalassemia.

Authors:  G F Temple; J C Chang; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

View more
  8 in total

1.  Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB.

Authors:  R A Srivastava; L Toth; N Srivastava; M E Hinsdale; N Maeda; A B Cefalu; M Averna; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

2.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

3.  Nonsense mutations in the human beta-globin gene affect mRNA metabolism.

Authors:  S J Baserga; E J Benz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  An initiation codon mutation (AUG----GUG) of the human alpha 1-globin gene. Structural characterization and evidence for a mild thalassemic phenotype.

Authors:  P Moi; F E Cash; S A Liebhaber; A Cao; M Pirastu
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

5.  Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema.

Authors:  D Frangi; M Cicardi; A Sica; F Colotta; A Agostoni; A E Davis
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

6.  Clinical features and molecular analysis of the alpha thalassemia/mental retardation syndromes. II. Cases without detectable abnormality of the alpha globin complex.

Authors:  A O Wilkie; H C Zeitlin; R H Lindenbaum; V J Buckle; N Fischel-Ghodsian; D H Chui; D Gardner-Medwin; M H MacGillivray; D J Weatherall; D R Higgs
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

7.  Nonsense mutation R1162X of the cystic fibrosis transmembrane conductance regulator gene does not reduce messenger RNA expression in nasal epithelial tissue.

Authors:  R Rolfini; G Cabrini
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait.

Authors:  A K Gupta; K A Kirchner; R Nicholson; J G Adams; A N Schechter; C T Noguchi; M H Steinberg
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.